Bridge Therapeutics

Speedtest

Improving the lives of patients living with chronic pain

Bridge Therapeutics, Inc. is a development-stage biotech company pursuing FDA approval of a patented (U.S. Patent #8410092) drug combination for the treatment of chronic pain in opioid experienced patients.

OUR MISSION

Our goal is to improve lives of patients living with chronic pain by developing new approaches to pain management that are safer, more effective, and non-addictive.

Patients are able to transition from standard opioid therapy to a drug with no symptoms of withdrawal. The drug produces no euphoric feeling in the patient, which is the main reason for the abuse of pain killers.

DR. GREG SULLIVAN